Triple negative breast cancer is common in younger and premenopausal women. Triple negative breast cancer is a vital area of study for both researchers and clinicians as it provides important information such as the current approaches used for the treatment of TNBC, treatment challenges, solutions, and prevalent of the illness among women. The overall objective of this paper is to present a summary of TNBC case, with the look of crucial information about the disease.
Search Strategy
For this discussion, PubMed search engine was used to obtain nursing journals articles on triple negative breast cancer trials. The researcher used PubMed to get the reviewed articles because it has different features of nursing studies and information of various nursing fields. The keywords that were typed in the PubMed engine to research on the TNBC topic include “triple negative breasts cancer human trails OR TNBC AND treatment OR treatment challenges and solutions OR the prevalence of TNBC OR the current approaches used to treat or diagnose the TNBC OR consequences of TNBC.” The journals that were accessed in the PubMed platform were published between 2015and 2017. From the starting point, the search involved 20 articles, but a review of the article’s topic reduced the article to 10. A final analysis of the contents of the ten articles reduced them to five articles, which the researcher used to give out the summary on the topic of this paper.
Summary
Through the search process, the researcher established that the treatment of TNBC has been a challenge for both the patients and clinicians because of fewer treatment options. The key risk factors that relate to TNBC as body max index and weight change factors (Bao et al., 2016). Typically, weight gain is mentioned as a common and persistent problem in breast cancer, especially to the younger patients being treated with chemotherapy (Bao, et al., 2016). Among the most common consequences of TNBC is death with the number of the people who are dying because of the disease continuing to increase (Bao et al., 2016). Wahba and El-Hadaad (2015) point out that TNBC is the most common cancer among female patients, with the disease causing up to 23% of all cancer cases relating to women. Swede et al. (2016) contends that although there is a slight improvement in mortality rate for African American breast cancer patients, the death rate for patients who are not in a good position to access care services or treatment continues to rise. As TNBC is highly prevalent in Africa American women, the illness is becoming a leading cause of death in women across the world (Swede et al., 2016).
Wahba and El-Hadaad (2015) noted that to treat TNBC, medical decisions are based on the traditional clinic-pathological factors such as patient tumour grade, size, and patient’s age. Similarly, Collignon et al. (2016) indicated that despite the challenges in the treatment of TNBC, clinicians or doctors use several systemic options to treat patients with TNBC. One of the popular treatment options quotedss in the study is chemotherapy (CT) treatment option (Collignon et al., 2016). Evidently, chemotherapy (CT) is presented as the best way that doctors in the modern hospitals are using to treat TNBC cases. Along the same argument, Tan (2015) writes that chemotherapy is the most effective method that clinicians in the present days are using in early stage treatment of TNBC. In this situation, physicians use chemotherapy method to conduct TNBC tests in phase II and phase III trials so that they can have patient stratification before therapy (Tan, 2015).
Bibliography
Bao, P.P., Cai, H., Peng, P., Gu, K., Su, Y., Shu, X.O. and Zheng, Y., 2016. Body mass index and weight change in relation to triple-negative breast cancer survival. Cancer Causes & Control, 27(2), pp.229-236. doi: 10.1007/s10552-015-0700-7.
Collignon, J., Lousberg, L., Schroeder, H. and Jerusalem, G., 2016. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer: Targets and Therapy, 8, pp.93-107. doi: 10.2147/BCTT.S69488.
Swede, H., Sarwar, A., Magge, A., Braithwaite, D., Cook, L.S., Gregorio, D.I., Jones, B.A., Hoag, J.R., Gonsalves, L., Salner, A.L. and Zarfos, K., 2016. Mortality risk from comorbidities independent of triple-negative breast cancer status: NCI-SEER-based cohort analysis. Cancer Causes & Control, 27(5), pp.627-636. doi: 10.1007/s10552-016-0736-3.
Tan, A.R., 2015. Triple-negative breast cancer: molecular subtypes and new targets for therapy. American Society of Clinical Oncology, e31-e39. doi:10.14694/EdBook_AM.2015.35.e31.
Wahba, H.A. and El-Hadaad, H.A., 2015. Current approaches in treatment of triple-negative breast cancer. Cancer biology & medicine, 12(2), pp.106-116. doi: 10.7497/j.issn.2095-3941.2015.0030.
